AI assistant
Sending…
Krystal Biotech, Inc. — Director's Dealing 2018
Jun 5, 2018
31006_dirs_2018-06-04_5053ad74-6f7e-40cb-9bd3-1051b205fe58.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2018-05-31
Reporting Person: JANNEY DANIEL (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-31 | Stock Option (Right to Buy) | $10.29 | A | 7500 | Acquired | 2028-05-31 | Common Stock (7500) | Direct |
Footnotes
F1: The options were awarded on May 31, 2018 and vest monthly over a one-year period.
More from Krystal Biotech, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 19
Earnings Release
2026
May 4
Interim / Quarterly Report
2026
May 4
Annual Report
2026
Apr 3
Proxy Solicitation & Information Statement
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4